The Immunobiology of Nipah Virus

被引:30
作者
Liew, Yvonne Jing Mei [1 ,2 ]
Ibrahim, Puteri Ainaa S. [1 ]
Ong, Hui Ming [1 ]
Chong, Chee Ning [1 ]
Tan, Chong Tin [3 ]
Schee, Jie Ping [3 ]
Roman, Raul Gomez [4 ]
Cherian, Neil George [4 ]
Wong, Won Fen [1 ]
Chang, Li-Yen [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Deputy Vice Chancellors Off Res & Innovat, Kuala Lumpur 50603, Malaysia
[3] Univ Malaya, Fac Med, Dept Med, Div Neurol, Kuala Lumpur 50603, Malaysia
[4] Coalit Epidem Preparedness Innovat CEPI, Vaccine Res & Dev, Askekroken 11, N-0277 Oslo, Norway
关键词
henipavirus infections; encephalitis; chiroptera; innate immunity; humoral immunity; cellular immunity; interferon type I; animal models; medical countermeasures; TO-PERSON TRANSMISSION; DATE PALM SAP; HENDRA VIRUS; CELL-DEATH; V-PROTEIN; ATTACHMENT GLYCOPROTEIN; CLINICAL-FEATURES; RECEPTOR-BINDING; HAMSTER MODEL; PIG-FARMERS;
D O I
10.3390/microorganisms10061162
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Nipah virus (NiV) is a highly lethal zoonotic paramyxovirus that emerged in Malaysia in 1998. It is a human pathogen capable of causing severe respiratory infection and encephalitis. The natural reservoir of NiV, Pteropus fruit bats, remains a continuous virus source for future outbreaks, although infection in the bats is largely asymptomatic. NiV provokes serious disease in various mammalian species. In the recent human NiV outbreaks in Bangladesh and India, both bats-to-human and human-to-human transmissions have been observed. NiV has been demonstrated to interfere with the innate immune response via interferon type I signaling, promoting viral dissemination and preventing antiviral response. Studies of humoral immunity in infected NiV patients and animal models have shown that NiV-specific antibodies were produced upon infection and were protective. Studies on cellular immunity response to NiV infection in human and animal models also found that the adaptive immune response, specifically CD4+ and CD8+ T cells, was stimulated upon NiV infection. The experimental vaccines and therapeutic strategies developed have provided insights into the immunological requirements for the development of successful medical countermeasures against NiV. This review summarizes the current understanding of NiV pathogenesis and innate and adaptive immune responses induced upon infection.
引用
收藏
页数:20
相关论文
共 152 条
  • [1] Abdullah S, 2012, NEUROL ASIA, V17, P71
  • [2] Isolation and molecular identification of Nipah virus from pigs
    AbuBakar, S
    Chang, LY
    Ali, ARM
    Sharifah, SH
    Yusoff, K
    Zamrod, Z
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (12) : 2228 - 2230
  • [3] Ademokun AA., 2010, IMMUNE RESPONSES PRI
  • [4] Nipah virus infection: A review
    Aditi
    Shariff, M.
    [J]. EPIDEMIOLOGY AND INFECTION, 2019, 147
  • [5] Neutrophil extracellular traps
    Amulic, Borko
    Hayes, Garret
    [J]. CURRENT BIOLOGY, 2011, 21 (09) : R297 - R298
  • [6] Nipah Virus Infection
    Ang, Brenda S. P.
    Lim, Tchoyoson C. C.
    Wang, Linfa
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (06)
  • [7] The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19)
    Arcanjo, Angelica
    Logullo, Jorgete
    Barreto Menezes, Camilla Cristie
    de Souza Carvalho Giangiarulo, Thais Chrispim
    dos Reis, Mirella Carneiro
    Migliani de Castro, Gabriellen Menezes
    Fontes, Yasmin da Silva
    Todeschini, Adriane Regina
    Freire-de-Lima, Leonardo
    Decote-Ricardo, Debora
    Ferreira-Pereira, Antonio
    Freire-de-Lima, Celio Geraldo
    Coutinho Barroso, Shana Priscila
    Takiya, Christina
    Conceicao-Silva, Fatima
    Savino, Wilson
    Morrot, Alexandre
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [8] Adaptive Immune Responses in Humans During Nipah Virus Acute and Convalescent Phases of Infection
    Arunkumar, Govindakarnavar
    Devadiga, Santhosha
    McElroy, Anita K.
    Prabhu, Suresh
    Sheik, Shahin
    Abdulmajeed, Jazeel
    Robin, Sudandiradas
    Sushama, Aswathyraj
    Jayaram, Anup
    Nittur, Sudheesh
    Shakir, Mohammed
    Kumar, Keeriyatt Govindan Sajeeth
    Radhakrishnan, Chandni
    Sakeena, Karayil
    Vasudevan, Jayasree
    Reena, Kalathil Joseph
    Sarita, Ragini Lohithakshan
    Klena, John D.
    Spiropoulou, Christina F.
    Laserson, Kayla F.
    Nichol, Stuart T.
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 (10) : 1752 - 1756
  • [9] First experience of ribavirin postexposure prophylaxis for Nipah virus, tried during the 2018 outbreak in Kerala, India
    Banerjee, Sayantan
    Niyas, Vettakkara Kandy Muhammed
    Soneja, Manish
    Shibeesh, Areekkare Purayil
    Basheer, Muhammed
    Sadanandan, Rajeev
    Wig, Naveet
    Biswas, Ashutosh
    [J]. JOURNAL OF INFECTION, 2019, 78 (06) : 497 - 499
  • [10] Remdesivir for the Treatment of Covid-19-Final Report
    Beigel, John H.
    Tomashek, Kay M.
    Dodd, Lori E.
    Mehta, Aneesh K.
    Zingman, Barry S.
    Kalil, Andre C.
    Hohmann, Elizabeth
    Chu, Helen Y.
    Luetkemeyer, Annie
    Kline, Susan
    de Castilla, Diego Lopez
    Finberg, Robert W.
    Dierberg, Kerry
    Tapson, Victor
    Hsieh, Lanny
    Patterson, Thomas F.
    Paredes, Roger
    Sweeney, Daniel A.
    Short, William R.
    Touloumi, Giota
    Lye, David Chien
    Ohmagari, Norio
    Oh, Myoung-don
    Ruiz-Palacios, Guillermo M.
    Benfield, Thomas
    Faetkenheuer, Gerd
    Kortepeter, Mark G.
    Atmar, Robert L.
    Creech, C. Buddy
    Lundgren, Jens
    Babiker, Abdel G.
    Pett, Sarah
    Neaton, James D.
    Burgess, Timothy H.
    Bonnett, Tyler
    Green, Michelle
    Makowski, Mat
    Osinusi, Anu
    Nayak, Seema
    Lane, H. Clifford
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (19) : 1813 - 1826